

**S-table. Underlying conditions of IPA patients**

<b>Underlying conditions</b>	All patients n=254	Proven n=51	Others n=203
<i>immunocompromised host factors</i>	66 (26.0%)	11 (21.6%)	55 (27.1%)
use of corticosteroid	46 (18.1%)	7 (13.7%)	39 (19.2%)
use of immunosuppressive agent	31 (12.2%)	4 (7.8%)	27 (13.3%)
chemotherapy	12 (4.7%)	3 (5.9%)	9 (4.4%)
solid organ transplantation	5 (2.0%)	3 (5.9%)	2 (1.0%)
neutropenia	7 (2.8%)	2 (3.9%)	5 (2.5%)
<i>Non-immunocompromised host factors</i>	188 (74.0%)	40 (78.4%)	148 (72.9%)
COPD	57 (22.4%)	3 (5.9%)	54 (26.6%)
diabetes	45 (17.7%)	15 (29.4%)	30 (14.8%)
viral pre-infection	18 (7.1%)	2 (3.9%)	16 (7.9%)
liver dysfunction	17 (6.7%)	6 (11.8%)	11 (5.4%)
bronchiectasis	6 (2.4%)	2 (3.9%)	4 (2.0%)
asthma	11 (4.3%)	3 (5.9%)	8 (4.0%)
renal insufficiency	9 (3.5%)	1 (2.0%)	8 (4.0%)
Without underlying diseases	36 (14.3%)	8 (15.7%)	24 (11.8%)

COPD: chronic obstructive pulmonary disease

EORTC/MSG: European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group

**S-Figure. Radiological presentations of IPA patients**

- A. cavity (grey arrow) and air crescent sign (black arrow)
- B. Halo sign (grey arrow)
- C. air crescent sign (grey arrow)
- D. wedge shaped consolidation (black arrow)
- E. patches distributing along the airway of right lower lobe bronchus (grey arrow)
- F. tree in bud sign (grey arrow)
- G. centrilobular nodules (black arrow)
- H. atelectasis (grey arrow) and airway wall thickness (black arrow)